solifenacin succinate


Also found in: Dictionary.
Related to solifenacin succinate: Tamsulosin, Vesicare

solifenacin succinate

VESIcare, Vesicare (UK)

Pharmacologic class: Anticholinergic

Therapeutic class: Renal and genitourinary agent

Pregnancy risk category C

Action

Antagonizes muscarinic receptors, reducing urinary bladder smooth-muscle contractions

Availability

Tablets: 5 mg, 10 mg

Indications and dosages

Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

Adults: 5 mg P.O. daily initially; may increase to 10 mg P.O. daily if well tolerated

Dosage adjustment

• Moderate hepatic impairment

• Severe renal impairment

• Concurrent use of potent CYP3A4 inhibitors (such as ketoconazole)

Contraindications

• Hypersensitivity to drug or its components

• Urinary retention

• Gastric retention

• Uncontrolled angle-closure glaucoma

Precautions

Use cautiously in:

• hepatic or renal impairment, bladder outflow obstruction, decreased GI motility, GI obstructive disorder, controlled angle-closure glaucoma, congenital or acquired QT interval prolongation

• increased risk of urinary retention or heat prostration

• pregnant or breastfeeding patients

• children (safety and efficacy not established).

Administration

• Give with liquids, with or without food. Make sure patient swallows tablet whole.

Adverse reactions

CNS: dizziness, depression, fatigue, asthenia

CV: hypertension

EENT: dry eyes, blurred vision, dry throat, pharyngitis

GI: nausea, vomiting, constipation, upper abdominal pain, dyspepsia, dry mouth

GU: urinary tract infection, urinary retention

Respiratory: cough

Skin: dry skin, rash, pruritus

Other: influenza, leg or foot edema

Interactions

Drug-drug. Anticholinergics: increased frequency or severity of adverse reactions

CYP3A4 inhibitors (such as ketoconazole): increased solifenacin blood level

Patient monitoring

• Monitor GI, renal, and hepatic function frequently.

• Monitor patient for ophthalmic disorders, especially angle-closure glaucoma. If present, stop drug until condition stabilizes.

Patient teaching

• Instruct patient to take drug with liquids, with or without food, and to swallow tablet whole.

• Advise patient to contact prescriber if severe abdominal pain or constipation lasting 3 or more days occurs.

• Caution patient to avoid driving and other hazardous activities until drug effects are known.

• Advise patient of risk for heat prostration; describe symptoms.

• Instruct patient to consult prescriber before taking over-the-counter products such as antihistamines because these may increase risk of side effects.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs mentioned above.

References in periodicals archive ?
The company added that the Solifenacin Succinate tablets is the generic version of Astellas Pharma's product VesiCare.
Solifenacin Succinate Tablets are contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug.
Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
Tenders are invited for Supply of Solifenacin succinate 10 mg tab
Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.
(NYSE: TEVA) (TASE: TEVA) has launched a generic version of VESIcare 1 (solifenacin succinate) Tablets, 5 mg and 10 mg, in the US, the company said.
M2 EQUITYBITES-May 8, 2018-Astellas Pharma awarded US FDA approval for sNDA for mirabegron & solifenacin succinate combination for treating OAB
M2 PHARMA-May 8, 2018-Astellas Pharma awarded US FDA approval for sNDA for mirabegron & solifenacin succinate combination for treating OAB
M2 EQUITYBITES-June 30, 2017-Astellas submits sNDA with the US FDA for the mirabegron and solifenacin succinate combination for the treatment of overactive bladder
M2 PHARMA-June 30, 2017-Astellas submits sNDA with the US FDA for the mirabegron and solifenacin succinate combination for the treatment of overactive bladder
The application seeks approval for mirabegron for use in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.